Dual Therapy in Depression

Approximately 1 in 5 individuals in the United States alone will experience depression during their lifetime. Current guidelines suggest that monotherapy may be used as initial therapy for major depressive disorder, but what evidence exists suggesting that starting dual anti-depressant therapy may have better outcomes? Join your host, Geoff Wall as he discusses a recent meta-analysis regarding dual therapy in depression.   The GameChanger:  For initial therapy or patients who are non-respondent to previous treatment, dual anti-depressant therapy may have a small, but significant impact on treatment outcomes, specifically treatment efficacy.   Show Segments 00:00 – Introductions 01:19 – Dual Therapy in Depression 11:57 – Which Anti-Depressant Combination? 15:27 – The GameChanger 18:37 – Closing Remarks   Host: Geoff Wall, PharmD., BCPS, FCCP, CGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health  References and resources: Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis  Redeem your CPE or CME credit here! Pharmacist members CME Need a membership? Join for CPE Credit  Join for CME Credit  Continuing Education Information: Learning Objectives: Describe which two classes of antidepressants had the highest remission rate when used together in this study  Discuss the pros and cons of this meta-analysis including the studies' heterogeneity  Dr. Wall is a member of the Janssen Speaker's Bureau. 0.05 CEU | 0.5 Hrs ACPE UAN: 0107-0000-22-143-H01-P Initial release date: 04/4/22 Expiration date: 04/4/2023 For more information https://www.ceimpact.com/podcast Follow CEimpact on Social Media:LinkedInInstagram